adapalene vs risankizumab
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of adapalene and risankizumab. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Differin
Skyrizi
No summary available.
Skyrizi is a medicine that can help reduce inflammation in your body. It is used to treat conditions like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Information not available.
Skyrizi is used to treat moderate to severe plaque psoriasis in adults. It can help reduce the red, scaly patches on your skin. Skyrizi also treats active psoriatic arthritis, which causes joint pain and swelling. Skyrizi can also treat moderately to severely active Crohn's disease and ulcerative colitis, which are inflammatory bowel diseases.
Information not available.
Skyrizi is a type of antibody that blocks a protein called interleukin-23 (IL-23). IL-23 causes inflammation in the body. By blocking IL-23, Skyrizi helps to reduce inflammation and the symptoms of certain diseases.
- • Dry skin
- • Contact dermatitis (skin rash)
- • Burning feeling on the skin where you put the medicine
- • Skin irritation
- • Upper respiratory infections (like a cold)
- • Headache
- • Fatigue
- • Injection site reactions (redness, pain, or swelling)
- • Tinea infections (like ringworm)
- Dry Skin 44,990
- Skin Burning Sensation 41,633
- Acne 39,264
- Erythema 38,379
- Skin Irritation 26,225
No adverse event reports.
No specific warnings noted.
Serious allergic reactions, including anaphylaxis, can happen. If you have an infection, tell your doctor. Skyrizi may increase your risk of getting an infection or make an existing infection worse. Your doctor will check you for tuberculosis (TB) before you start Skyrizi. For inflammatory bowel disease, Skyrizi can cause liver problems. Your doctor will check your liver before and during treatment.
No pregnancy information available.
Tell your doctor if you are pregnant or plan to become pregnant. It is not known if Skyrizi will harm your unborn baby. There is a pregnancy registry to track outcomes in women who use Skyrizi during pregnancy. Call 1-877-302-2161 to enroll.
Also Compare, Nearby Drugs
Compare adapalene with
Compare risankizumab with
How to Read This adapalene vs risankizumab Comparison
adapalene is classified in the Retinoid (Topical) drug class, while risankizumab sits within the Anti-IL-23 Monoclonal Antibody class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are split between OTC and prescription status, which affects access and supervision.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, adapalene has 190,491 submissions while risankizumab has 0. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for adapalene or risankizumab.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.